Market Research Logo

Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023) -- By Region (North America, Europe, APAC), By Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China)

Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023) -- By Region (North America, Europe, APAC), By Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China)

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global biopharmaceutical Contract Manufacturing Organisation (CMO) market. The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” analyses the global market as well as the market by Region (North America, Europe and Asia Pacific) and by Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China.

According to Azoth Analytics research report “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)”, the global market value is projected to display a steady growth represented by a CAGR of 14.36% during the forecast period of 2018 – 2023.

Amongst the regions, Europe accounts for the largest share by value in global Bio CMO market in 2017. Additionally, Asia Pacific will be a growing region in the forecasted period, 2018-2023 as population is increasing along with growing number of pharmaceutical requirements. Growing number of chronic diseases is also supporting the market of Bio CMO industry.

The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” has covered and analyzed the potential of Global Bio CMO Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global Bio CMO market. Additionally, the report also assesses the financial performance and strategies of various companies operating in the Biopharmaceutical CMO market.

Scope of the Report

Global Bio CMO Market (Actual Period: 2013-2017, Forecast Period: 2018-2023

  • Global Bio CMO Market – By value
  • By Type – Mammalian & Microbial
Regional Markets – North America, Europe, APAC (Actual Period: 2013-2017, Forecast Period: 2018-2023)
  • Bio CMO Market – By value
Country Analysis - U.S, Denmark, Germany, Switzerland, Korea, Japan, China and Others
  • Bio CMO Market – By value
Other Report Highlights
  • Market Dynamics – Drivers and Restraints
  • Company Analysis – Lonza, Boehringer Ingelheium, Samsung Biologics, Wuxi Biologics


1. Research Methodology
2. Executive Summary
3. Biopharmaceutical CMO Outlook
4. Global Bio CMO Market: Growth and Forecast
4.1 Global Bio CMO Market, By Value (2013-2017) (USD Billion)
Table 1: Global In House Manufacturing By Value, 2013-2017 (USD Billion)
4.2 Global Bio CMO Market, By Value (2018-2023) (USD Billion)
Table 2: Global In House Manufacturing By Value, 2013-2017 (USD Billion)
5. Global Bio CMO Market: Segment Analysis
Table 3: Global Bio CMO Market Size, By Value, 2013-2017 (USD Billion)
Table 4: Global Biologics market Outlook, 2012-2016 (In Billion )
Table 5: Global Biologics market Outlook, 2012-2016 (In Billion)
Table 6: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Table 7: Number of people with diabetes worldwide and per region in 2017 and 2045, (20-79 years)
Table 8: Diabetes Prevalence, By Country, in % of population ages 20 to 79 in 2017
Table 9: Global Bio CMO Market Size, By Value, 2018-2023 (USD Billion)
Table 10: Global Bio CMO Market Size, By Segment, 2017 (%)
Table 11: Global Bio CMO Market Size, By Segment, 2023 (%)
6. North America Bio CMO Market: Growth and Forecast
6.1 North America Market, By Value (2013-2017)(USD Billion)
Table 12: North America Bio CMO Size, By Value, 2013-2017 (USD Billion)
6.2 North America Market, By Value (2018-2023)(USD Billion)
Table 13: North America Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Table 14: North America GDP, 2013-2017 (USD Trillion)
Table 15: North America GDP, By Select Country, 2016 (USD Trillion)
Table 16: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
Table 17: Number of Citizen 65 years and above, USA and Canada in Million 2016
Table 18: Number of Citizen 65 years and above, USA and Canada in Million 2060
Table 19: North America Prevalence of Gynecological Disorders (2012-2016)
Table 20: Total Number of People with North America Neglected Tropical Disorders (2012-2016)
Table 21: Total Number of People in North America with Different Type of Cardiovascular Disease in 2016
Table 22: North America DALYs of Ischemic Heart Disease(2013-2016 %)
Table 23: North America DALYs of Chronic Kidney Disease(2013-2016 %)
Table 24: North America DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 25: North America DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 26: North America DALYs of Diabetes Mellitus(2013-2016 %)
7. U.S Bio CMO Market, By indications
Table 27: United States Prevalence of Diabetes (Per 1,00,000 )2013-2016
Table 28: United States Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Table 29: Prevalence of Neurological Disorders in United States (2016, Million)
Table 30: United States Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Table 31: United States DALYs of Ischemic Heart Disease (2013-2016 %)
Table 32: United States DALYs of Chronic Kidney Disease(2013-2016 %)
Table 33: United States DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 34: United States DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 35: United States DALYs of Diabetes Mellitus (2013-2016 %)
8. Canada Bio CMO Market , By Indications
Table 36: Canada Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Table 37: Canada Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Table 38: Canada Total Number of People With Sense Organ Disorders (2012-2016)
Table 39: Canada Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Table 40: Canada DALYs of Ischemic Heart Disease (2013-2016 %)
Table 41: Canada DALYs of Chronic Kidney Disease(2013-2016 %)
Table 42: Canada DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 43: Canada DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 44: Canada DALYs of Diabetes Mellitus (2013-2016 %)
9. Europe Bio CMO Market: Growth and Forecast
9.1 Europe Market, By Value (2013-2017)(USD Billion)
Table 45: Europe Bio CMO Size, By Value, 2013-2017 (USD Billion)
9.2 Europe Market, By Value (2018-2023)(USD Billion)
Table 46: Europe Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Table 47: Number Deaths due to cancer in Europe 2016
Table 48: Share of older population 65 years and above as percentage of total population
Table 49: Western Europe Prevalence of Gynecological (2012-2016, Million)
Table 50: Western Europe Prevalence of Musculoskeletal Disorders (2012-2016, Million)
Table 51: Total Number of People With Cardiovascular Disorders in Western Europe, By Type,2016
Table 52: Western Europe DALYs of Ischemic Heart Disease (2013-2016), in %
Table 53: Western Europe DALYs of Chronic Kidney Disease(2013-2016)in %
Table 54: Western Europe DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 55: Western Europe DALYs of Alzheimer Disease and Other Dementias (2013-2016 )in %
Table 56: Western Europe DALYs of Diabetes Mellitus (2013-2016 )in %
10. Germany Bio CMO Market, By indications
Table 57: Germany Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Table 58: Total Number of People With Infectious Disorder in Germany (2012-2016)
Table 59: Germany Prevalence of Neurological Disorders (2012-2016, Million)
Table 60: Germany Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Table 61: Germany DALYs of Ischemic Heart Disease (2013-2016), in %
Table 62: Germany DALYs of Chronic Kidney Disease (2013-2016), in %
Table 63: Germany DALYs of Chronic Obstructive Pulmonary Disease(2013-2016), in%
Table 64: Germany DALYs of Alzheimer Disease and Other Dementias (2013-2016), %
Table 65: Germany DALYs of Diabetes Mellitus (2013-2016), %
11. U.K Bio CMO Market, By indications
Table 66: United Kingdom DALYs of Ischemic Heart Disease (2013-2016), %
Table 67: United Kingdom DALYs of Chronic Kidney Disease(2013-2016), %
Table 68: United Kingdom DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 69: United Kingdom DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 70: United Kingdom DALYs of Diabetes Mellitus (2013-2016 %)
Table 71: United Kingdom Prevalence of Cardiovascular Disorders (Per 1,00,000), 2013-2016
Table 72: United Kingdom Prevalence of Diabetes Mellitus (Per 1,00,000), 2013-2016
Table 73: United Kingdom Prevalence of Musculoskeletal Disorders (Per 1,00,000), 2013-2016
12. France Bio CMO Market, By indications
Table 74: France DALYs of Ischemic Heart Disease (2013-2016 %)
Table 75: France DALYs of Chronic Kidney Disease(2013-2016 %)
Table 76: France DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 77: France DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 78: France DALYs of Diabetes Mellitus (2013-2016 %)
13. APAC Bio CMO Market: Growth and Forecast
13.1 APAC Market, By Value (2013-2017)(USD Billion)
Table 79: APAC Bio CMO Size, By Value, 2013-2017 (USD Billion)
13.2 APAC Market, By Value (2018-2023)(USD Billion)
Table 80: APAC Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Table 81: South East Asia, East Asia, Oceania , DALYs of Ischemic Heart Disease (2013-2016 %)
Table 82: South East Asia, East Asia, Oceania DALYs of Chronic Kidney Disease(2013-2016 %)
Table 83: South East Asia, East Asia, Oceania DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 84: South East Asia, East Asia, Oceania DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 85: South East Asia, East Asia, Oceania DALYs of Diabetes Mellitus (2013-2016 %)
14. China Bio CMO Market, By indications
Table 86: China DALYs of Ischemic Heart Disease (2013-2016 %)
Table 87: China DALYs of Chronic Kidney Disease(2013-2016 %)
Table 88: China DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 89: China DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 90: China DALYs of Diabetes Mellitus (2013-2016 %)
Table 91: China Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Table 92: China Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Table 93: China Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
15. India Bio CMO Market, By indications
Table 94: India Prevalence of Diabetes Mellitus (Per 1,00,000)2013-2016
Table 95: India Prevalence of Musculoskeletal Disorders (Per 1,00,000) 2013-2016
Table 96: India Prevalence of Cardiovascular Disorders (Per 1,00,000) 2013-2016
Table 97: Total Number of People With Infectious Disorder in India (2012-2016)
Table 98: India DALYs of Ischemic Heart Disease (2013-2016 %)
Table 99: India DALYs of Chronic Kidney Disease(2013-2016 %)
Table 100: India DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 101: India DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 102: India DALYs of Diabetes Mellitus (2013-2016 %)
16. Japan Bio CMO Market, By indications
Table 103: Japan DALYs of Ischemic Heart Disease (2013-2016 %)
Table 104: Japan DALYs of Chronic Kidney Disease(2013-2016 %)
Table 105: Japan DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Table 106: Japan DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Table 107: Japan DALYs of Diabetes Mellitus(2013-2016 %)
Table 108: Japan Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Table 109: Japan Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Table 110: Japan Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
17. Bio CMO Market: Country Analysis
17.1 U.S Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 111: US Bio CMO Size, By Value, 2013-2023 (USD Billion)
Table 112: US Pharmaceutical Spending 2013-2017 in USD Billion
Table 113: Revenue of companies engaged in speciality pharmacy in US 2016 (in million USD)
17.2 Denmark Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 114: Denmark Bio CMO Size, By Value, 2013-2023 (USD Billion)
17.3 Germany Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 115: Germany Bio CMO Size, By Value, 2013-2023 (USD Billion)
Table 116: Revenue of Germany Pharmaceutical Industry 2012-2016 in Billion USD
17.4 Switzerland Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 117: Switzerland Bio CMO Size, By Value, 2013-2023 (USD Billion)
Table 118: Swiss pharmaceutical industry export 2000
Table 119: Swiss pharmaceutical industry export 2016
17.5 Korea Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 120: Korea Bio CMO Size, By Value, 2013-2023 (USD Billion)
17.6 Japan Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 121: Japan Bio CMO Size, By Value, 2013-2023 (USD Billion)
Table A: Japan Biopharmaceutical Market (100 million USD)
17.7 China Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 122: China Bio CMO Size, By Value, 2013-2023 (USD Billion)
Table 123: China Expenditure on Health and Medical Care 2012-2018 (in USD Billion)
17.8 Others Bio CMO Market, By Value (2013-2023) (USD Billion)
Table 124: Other’s Bio CMO Size, By Value, 2013-2023 (USD Billion)
18. Global Bio CMO Market Dynamics
18.1 Global Bio CMO Market Drivers
18.2 Global Bio CMO Market Challenges
19. Company Profiles
19.1 Lonza
Table 125: Lonza, Net Sales, 2014-2017 (In Billion USD)
19.2 Boehringer Ingelheium
Table 126: Boehringer Ingelheim, Net Sales, 2013-2016 (In Million USD)
Table 127: Boehringer Ingelheim Sales by Region, 2016
Table 128: Boehringer Ingelheim Sales by Segment, 2016
19.3 Samsung Biologics
Table 129: Samsung Biologics, Net Sales, 2014-2017 (In Million USD)
Table 130: Samsung Biologics, Biomedicine manufacturing plants, 2017
19.4 Wuxi Biologics
Table 131: Wuxi Biologics, Net Sales, 2013-2016 (In Million USD)
Table 132: Wuxi Biologics, Sales by Region, 2016
Table 133: Wuxi Biologics, Sales by Segment, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report